Center for Infectious Diseases in India

Studies/Projects
Publications

Assessment of Active Tuberculosis amongst Asymptomatic HIV-infected Patients in Kakinada, India

Post Date:

2009-07-23

|

Countries:

This study was conducted in 2008. Tuberculosis (TB) is a major public health threat in India and is the leading cause of morbidity and mortality amongst people living with HIV/AIDS worldwide.1 According to the WHO, India accounts for one-fifth of the global TB incident cases...

A5253: Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals

Post Date:

2009-03-19

|

Countries:

|

Clinical Sites:

This study was terminated October 15, 2014. An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with projected rates of requirement for ARV therapy extending to more than 10 million in sub-Saharan Africa...

P1070: Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-Infected and HIV/TB Co-Infected Infants and Children ≥ 3 Months to < 36 Months of Age

Post Date:

2008-12-05

|

Countries:

|

Clinical Sites:

This study ended March 10, 2015. This multi-country trial was conducted in India, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe, under the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and funded by the U.S. National Institutes of...

BWI CTU: Baltimore-Washington-India Clinical Trials Unit

Post Date:

2007-02-02

|

Countries:

|

Clinical Sites:

Comprising clinical trial sites at Johns Hopkins Medicine in Baltimore, Whitman Walker Health in Washington, DC, and the BJGMC-CCGHE collaboration in Pune, India, the Baltimore-Washington-India Clinical Trials Unit (BWI-CTU) is one of only 25 international HIV/TB clinical trial sites funded by the...

BJGMC-JHU Fogarty HIV-TB Training Program

Post Date:

2007-01-01

|

Countries:

|

Clinical Sites:

Funded by the Fogarty International Center at the National Institutes of Health, the JHU Fogarty program has nearly 20 years of success with providing training, professional development, and mentorship to clinicians and scientists in low and middle income countries. CCGHE's latest efforts in...

Pages

Assessment of lung function in successfully treated tuberculosis reveals high burden of ventilatory defects and COPD

Post Date:

2019-05-23

|

Countries:

Publication:

PLoS One

New in PLoS One: We found a high burden of lung function defects and COPD in tuberculosis cases who successfully completed treatment, suggesting a need for lung function screening as part of patient management.

Subtherapeutic rifampicin concentration is associated with unfavourable tuberculosis treatment outcomes

Post Date:

2019-05-10

|

Countries:

Publication:

Clinical Infectious Diseases

Rifampicin concentrations were sub-therapeutic in most Indian patients taking a thrice-weekly TB regimen

Respiratory health status is associated with treatment outcomes in pulmonary tuberculosis

Post Date:

2019-04-19

|

Countries:

Publication:

The International Journal of Tuberculosis and Lung Disease

BACKGROUND: The association between respiratory impairment and tuberculosis (TB) treatment outcomes is not clear. METHODS: We prospectively evaluated respiratory health status, measured using the Saint George's Respiratory Questionnaire (SGRQ), in a cohort of new adult pulmonary TB cases during and...

Feasibility of identifying household contacts of rifampin- and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease

Post Date:

2019-03-28

|

Countries:

Publication:

Clinical Infectious Diseases

We assessed multidrug-resistant tuberculosis (MDR-TB) cases and their household contacts (HHCs) to inform the development of an interventional clinical trial.

Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex

Post Date:

2019-03-18

Publication:

Clinical Infectious Diseases

Abstract Tuberculosis is the primary infectious disease killer worldwide, with a growing threat from multidrug- resistant cases. Unfortunately, classic growth-based phenotypic drug susceptibility testing (DST) remains difficult, costly and time-consuming, while current rapid molecular testing...

One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis

Post Date:

2019-03-14

Publication:

New England Journal of Medicine

Exciting findings from A5279: One month of Rifapentine with isonaizid is as effective as a 9-month course of isoniazid alone!

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

Post Date:

2019-01-28

|

Countries:

|

Clinical Sites:

Hinduja Hospital

Publication:

BMC Infectious Diseases

BACKGROUND: India has the world's highest tuberculosis burden, and Mumbai is particularly affected by multidrug resistant tuberculosis (MDR-TB). WHO recommends short, intensive treatment ("Short Course") for previously untreated pulmonary MDR-TB patients but does not require universal...

Symptom screening for active tuberculosis in pregnant women living with HIV

Post Date:

2019-01-24

Publication:

Cochrane Database of Systematic Reviews

This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows: To assess the accuracy of the four-symptom screen (cough, fever, night sweats, or weight loss) for identifying active TB in pregnant PLHIV who are screened in an outpatient or community setting...

HIV testing uptake among the household contacts of multidrug-resistant tuberculosis index cases in eight countries

Post Date:

2019-01-07

|

Countries:

|

Clinical Sites:

Publication:

International Journal of Tuberculosis and Lung Disease

International Journal of Tuberculosis and Lung Disease : The Indo-JHU Clinical Research Parentership participated in this multinational study to determine if it's feasible to provide HIV testing for household contacts of MDR-TB cases.

Is there a connection between gestational diabetes, human immunodeficiency virus infection, and tuberculosis?

Post Date:

2019-01-01

|

Countries:

|

Clinical Sites:

Publication:

International Journal of Tuberculosis and Lung Disease

IJTLD article reviews the epidemiology and immunology of gestational diabetes and finds there's a lot we don't know about interactions between diabetes, pregnancy, and tuberculosis in both HIV+/- women

Building capacity for advances in tuberculosis research: Proceedings of the third RePORT International Meeting. Tuberculosis (Edinb)

Post Date:

2018-12-15

Publication:

Tuberculosis (Edinb)

Abstract RePORT International is a global network of research sites in India, Brazil, Indonesia, South Africa, China, and the Philippines dedicated to collaborative tuberculosis research in the context of HIV. A standardized research protocol (the Common Protocol) guides the enrollment...

The global landscape of tuberculosis therapeutics

Post Date:

2018-11-07

Publication:

Annual Review of Medicine

Abstract Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections...

Barriers to screening and isoniazid preventive therapy for child contacts of tuberculosis patients

Post Date:

2018-10-01

|

Countries:

|

Clinical Sites:

Publication:

International Journal of Tuberculosis and Lung Disease

Universal, timely TB screening and IPT for exposed children are urgently needed to reduce pediatric TB in India

Inflammation and micronutrient biomarkers predict clinical HIV treatment failure and incident active TB in HIV-infected adults: a case-control study

Post Date:

2018-09-24

|

Countries:

|

Clinical Sites:

Publication:

BMC Medicine

Factors identified through exploratory factor analysis were associated with adverse outcomes in HIV-infected individuals.

Report of the Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments

Post Date:

2018-09-17

Publication:

WHO Task Force on Introduction of New TB Drugs and Treatment Regimens

Dr. Amita Gupta was a member of this TB technical consultation, convened in March 2018 in Switzerland.

Ovarian mass - tuberculosis or malignancy? Need for early intensified evaluation

Post Date:

2018-09-14

|

Countries:

|

Clinical Sites:

Publication:

EXCLI Journal

Letter to the Editor Dear Editor, We read with interest the case report by Chien et al. on Peritoneal Tuberculosis (TB) mimicking ovarian cancer (Chien et al., 2016[1]). We want to congratulate the authors on this case report. We encountered a similar case in our clinical setting in western India...

The association of household fine particulate matter and kerosene with tuberculosis in women and children in Pune, India

Post Date:

2018-09-07

|

Countries:

|

Clinical Sites:

Publication:

Occupational and Environmental Medicine

Use of kerosene cooking fuel is positively associated with TB in women and children in our analysis using reported sources of exposure.

Failure in TB control: why should the rapid diagnostic test bear the blame?

Post Date:

2018-09-01

Publication:

International Journal of Tuberculosis and Lung Disease

Dr. Sachit Atre's correspondence published in the International Journal of Tuberculosis and Lung Disease.

Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003)

Post Date:

2018-09-01

|

Clinical Sites:

Publication:

International Journal of Tuberculosis and Lung Disease

Current guidelines recommend evaluation of the household contacts of individuals with multidrug-resistant tuberculosis; however, implementation of this policy is challenging.

The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment

Post Date:

2018-08-20

|

Countries:

|

Clinical Sites:

Publication:

Antimicrobial Agents and Chemotherapy

DM and higher HbA1c increased the risk of not achieving therapeutic targets for pyrazinamide, but higher pyrazinamide concentrations were asociated with worse microbiologic and clinical outcomes

Pages